Measurement of posttransfusion red cell survival with the biotin label

Transfusion Medicine Reviews

Volumn 28, Issue 3, 2014, Pages 114-125

  Mock, Donald M ^a   Widness, John A ^b   Veng Pedersen, Peter ^c   Strauss, Ronald G ^b   Cancelas, Jose A ^d   Cohen, Robert M ^e,f   Lindsell, Christopher J ^e   Franco, Robert S ^e  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Application; Biotin; Multiple density; Nonradioactive; Red cell survival; Red cell volume; Vulnerable population

Indexed keywords

BIOTIN;

ANEMIA; ANTIGEN ANTIBODY REACTION; BIOTINYLATION; BLOOD CELL COUNT; BLOOD GROUP ABO SYSTEM; CELL LABELING; CELL MIGRATION; CHRONIC DISEASE; DIABETES MELLITUS; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; ERYTHROPHAGOCYTOSIS; GESTATIONAL AGE; HUMAN; ISOTOPE LABELING; LONG TERM SURVIVAL; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MEASUREMENT ACCURACY; PLASMA VOLUME; PREMATURITY; REVIEW; SICKLE CELL ANEMIA; TRANSFUSION MEDICINE; CELL AGING; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; ERYTHROCYTE; INFANT; NEWBORN; PATIENT SAFETY; PROCEDURES; REFERENCE VALUE; THEORETICAL MODEL; TIME;

BIOTIN; BIOTINYLATION; CELL AGING; CELL SURVIVAL; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS; INFANT; INFANT, NEWBORN; MODELS, THEORETICAL; PATIENT SAFETY; REFERENCE VALUES; TIME FACTORS;

EID: 84903487151     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2014.03.003     Document Type: Review

References (93)

1. Franco R.S. The measurement and importance of red cell survival. Am J Hematol 2009, 84:109-114.
2. Franco R.S., Lohmann J., Silbertein E.B., Mayfiled-Pratt G., Palascak M., Nemeth T.A., et al. Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells. J Clin Investig 1998, 101:2730-2740.
3. Cohen R.M., Franco R.S., Khera P.K., Smith E.P., Lindsell C.J., Ciraolo P.J., et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008, 112:4284-4291.
4. Shemin D., Rittenberg D. The life span of the human red blood cell. J Biol Chem 1946, 166:627-636.
5. 51Cr labeled red cells. Transfusion 1999, 39:149-155.
6. Nalbant D., Bhandary P., Matthews N.I., Schmidt R.L., Bogusiewicz A., Cress G.A., et al. Comparison of multiple red cell volume methods performed concurrently in premature infants following allogeneic transfusion. Pediatr Res 2013, 74:592-600.
7. Mollison P.L. Further observations on the normal survival curve of 51 Cr-labelled red cells. Clin Sci 1961, 21:21-36.
8. Moroff G., Sonmer P.R., Button L.N. Proposed standardization of methods for determining the 24-hour survival of stored red cells. Transfusion 1984, 24:109-114.
9. Cancelas J.A., Dumont L.J., Rugg N., Szczepiorkowski Z.M., Herschel L., Siegel A., et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011, 51:2367-2376.
10. Cancelas J.A., Rugg N., Fletcher D., Pratt P.G., Worsham D.N., Dunn S.K., et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011, 51:1460-1468.
11. Avent N.D. Glycophorin C ligation: another biochemical pathway in red blood cell senescence?. Transfusion 2013, 53:2111.
12. Franco R.S., Puchulu-Campanella M.E., Barber L.A., Palascak M.B., Joiner C.H., Low P.S., et al. Changes in the properties of normal human red blood cells during in vivo aging. Am J Hematol 2013, 88:44-51.
13. Cohen R.M., Lindsell C.J. When the blood glucose and the HbA(1c) don't match: turning uncertainty into opportunity. Diabetes Care 2012, 35:2421-2423.
14. Bosch F.H., Werre J.M., Roerdinkholder-Stoelwinder B., Huls T.H., Willekens F.L., Halie M.R. Characteristics of red blood cell populations fractionated with a combination of counterflow centrifugation and Percoll separation. Blood 1992, 79:254-260.
15. Willekens F.L., Bosch F.H., Roerdinkholder-Stoelwinder B., Groenen-Dopp Y.A., Werre J.M. Quantification of loss of haemoglobin components from the circulating red blood cell in vivo. Eur J Haematol 1997, 58:246-250.
16. Willekens F.L., Roerdinkholder-Stoelwinder B., Groenen-Dopp Y.A., Bos H.J., Bosman G.J., van den Bos A.G., et al. Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesiculation. Blood 2003, 101:747-751.
17. Clark M.R. Senescence of red blood cells: progress and problems. Physiol Rev 1988, 68:503-554.
18. Galili U., Flechner I., Knyszynski A., Danon D., Rachmilewitz E.A. The natural anti-alpha-galactosyl IgG on human normal senescent red blood cells. Br J Haematol 1986, 62:317-324.
19. Arese P., Turrini F., Schwarzer E. Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. Cell Physiol Biochem 2005, 16:133-146.
20. Kay M.M., Lin F.B. Molecular mapping of the active site of an aging antigen: senescent cell antigen requires lysine(s) for antigenicity and is located on an anion-binding segment of band 3 membrane transport protein. Gerontology 1990, 36:293-305.
21. Waugh R.E. Effects of 2,3-diphosphoglycerate on the mechanical properties of erythrocyte membrane. Blood 1986, 68:231-238.
22. Low P.S., Waugh S.M., Zinke K., Drenckhahn D. The role of hemoglobin denaturation and band 3 clustering in red blood cell aging. Science 1985, 227:531-533.
23. Snyder L.M., Leb L., Piotrowski J., Sauberman N., Liu S.C., Fortier N.L. Irreversible spectrin-haemoglobin crosslinking in vivo: a marker for red cell senescence. Br J Haematol 1983, 53:379-384.
24. Christian J.A., Rebar A.H., Boon G.D., Low P.S. Senescence of canine biotinylated erythrocytes: increased autologous immunoglobulin binding occurs on erythrocytes aged in vivo for 104 to 110 days. Blood 1993, 82:3469-3473.
25. Dale G.L., Daniels R.B. Quantitation of immunoglobulin associated with senescent erythrocytes from the rabbit. Blood 1991, 77:1096-1099.
26. Boas F.E., Forman L., Beutler E. Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. Proc Natl Acad Sci U S A 1998, 95:3077-3081.
27. Gifford S.C., Derganc J., Shevkoplyas S.S., Yoshida T., Bitensky M.W. A detailed study of time-dependent changes in human red blood cells: from reticulocyte maturation to erythrocyte senescence. Br J Haematol 2006, 135:395-404.
28. Gifford S.C., Yoshida T., Shevkoplyas S.S., Bitensky M.W. A high-resolution, double-labeling method for the study of in vivo red blood cell aging. Transfusion 2006, 46:578-588.
29. DeJong K.B.A., Emerson R.K., Kuypers F.A. Flippase activity decreases throughout erythrocyte life-span in normal and sickle mice [abstract]. Blood 2006, 108.
30. Lorand L., Murthy S.N., Khan A.A., Xue W., Lockridge O., Chishti A.H. Transglutaminase-mediated remodeling of the human erythrocyte membrane skeleton: relevance for erythrocyte diseases with shortened cell lifespan. Adv Enzymol Relat Areas Mol Biol 2011, 78:385-414.
31. +channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003, 285:C1553-C1560.
32. Khandelwal S., van Rooijen N., Saxena R.K. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 2007, 47:1725-1732.
33. Oldenborg P.A., Gresham H.D., Chen Y., Izui S., Lindberg F.P. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood 2002, 99:3500-3504.
34. Burger P., Hilarius-Stokman P., de Korte D., van den Berg T.K., van Bruggen R. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 2012, 119:5512-5521.
35. Ashby W. The determination of the length of life of transfused blood corpuscles in man. J Exp Med 1919, 29:267-281.
36. International Committee for Standardization in Haematology Recommended methods for radioisotope red-cell survival studies. Br J Haematol 1980, 45:659-666.
37. International Committee for Standardization in Haematology Recommended methods for measurement of red-cell and plasma volume. J Nucl Med 1980, 21:793-800.
38. Korubin V., Maisey M.N., McIntyre P.A. Evaluation of technetium-labeled red cells for determination of red cell volume in man. J Nucl Med 1972, 13:760-762.
39. 14C-cyanate as a tag for red cell survival in normal and uremic man. J Lab Clin Med 1977, 89:823-828.
40. Johnson P.F., Tothill P., Donaldson G.W. Stable chromium as a tracer for red cells, with assay by neutron activation analysis. Int J Appl Radiat Isot 1969, 20:103-108.
41. 51Cr red cell survival studies. Br J Haematol 1974, 26:179-184.
42. Klein H., Anstee D. Mollison's blood transfusion in clinical medicine. Anstee D editors 2006, 352-405. Blackwell Publishing, London. H. Klein (Ed.).
43. Klein H., Anstee D. Mollison's blood transfusion in clinical medicine 2006, 406-454. Blackwell Publishing, London. H. Klein, D. Anstee (Eds.).
44. Mollison P., Veall N. The use of the isotope 51Cr as a label for red cells. Br J Haematol 1955, 1:62-74.
45. Ebaugh F.G., Emerson C.P., Ross J.F. The use of radioactive chromium 51 as an erythrocyte tagging agent for the determination or red cell survival in vivo. J Clin Investig 1953, 32:1260-1276.
46. 51Cr survival curves. Br J Haematol 1971, 20:527-536.
47. 51Cr red cell survival studies. Br J Haematol 1974, 26:179-184.
48. Bell E.F., Nahmias C., Sinclair J.C., Zipursky A. Changes in circulating red cell volume during the first 6weeks of life in very-low-birth-weight infants. Pediatr Res 2014, 75:81-84.
49. Mock D., Matthews N., Zhu S., Burmeister L., Zimmerman M., Strauss R., et al. Red blood cell (RBC) volume can be independently determined in vivo in humans using RBCs labeled at different densities of biotin. Transfusion 2011, 51:148-157.
50. Mock D.M., Lankford G.L., Widness J.A., Burmeister L.F., Kahn D., Strauss R.G. Accelerated removal of antibody-coated red blood cells from the circulation is accurately tracked by a biotin label. Transfusion 2012, 52:1097-1105.
51. Cavill I., Trevett D., Fisher J., Hoy T. The measurement of the total volume of red cells in man: a non-radioactive approach using biotin. Br J Haematol 1988, 70:491-493.
52. Bogusiewicz A., Mock N.I., Mock D.M. Instability of the biotin-protein bond in human plasma. Anal Biochem 2004, 327:156-161.
53. 51Cr labeled red cells. Transfusion 1999, 39:156-162.
54. Bogusiewicz A., Mock N.I., Mock D.M. Release of biotin from biotinylated proteins occurs enzymatically and nonenzymatically in human plasma. Anal Biochem 2004, 331:260-266.
55. Mock D.M., Lankford G.L., Widness J.A., Burmeister L.F., Kahn D., Strauss R.G. RBCs labeled at two biotin densities permit simultaneous and repeated measurements of circulating RBC volume. Transfusion 2004, 44:431-437.
56. Hudson I., Cooke A., Holland B., Houston A., Jones J.G., Turner T., et al. Red cell volume and cardiac output in anaemic preterm infants. Arch Dis Child 1990, 65:672-675.
57. Mock D.M., Matthews N.I., Zhu S., Strauss R.G., Schmidt R.L., Nalbant D., et al. Red blood cell (RBC) survival determined in humans using RBCs labeled at multiple biotin densities. Transfusion 2011, 51:1047-1057.
58. Luten M., Roerdinkholder-Stoelwinder B., Schaap N.P., de Grip W.J., Bos H.J., Bosman G.J. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. Transfusion 2008, 48:1478-1485.
59. Widness J., Nalbant D., Matthews N., Strauss R., Schmidt R., Cress G., et al. Tracking donor RBC survival in premature infants: agreement of multiple populations of biotin labeled RBCs with Kiddantigen mismatched RBCs. Pediatr Res 2013, 74:689-697.
60. Strauss R., DJ K., Mock D., Matthews N., Nalbant D., Schmidt R., et al. Post-transfusion red cell survival of neonatal autologous and adult donor biotin labeled RBCs, measured concurrently, are not different. Transfusion 2013, 53:31A.
61. Garratty G., Arndt P.A. Applications of flow cytofluorometry to red blood cell immunology. Cytometry 1999, 38:259-267.
62. Dumont L.J., AuBuchon J.P. Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials. Transfusion 2008, 48:1053-1060.
63. Dumont L.J., AuBuchon J.P. Evaluation of proposed FDA criteria for evaluation of radiolabeled red cell recovery trials http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4355S1-00-index.html.
64. Kuruvilla D.J., Nalbant D., Widness J.A., Veng-Pedersen P. Mean remaining lifespan: a new clinically relevant parameter for assessing the quality of transfused blood. Transfusion 2014, 10.1111/trf.12562.
65. Lindsell C.J., Franco R.S., Smith E.P., Joiner C.H., Cohen R.M. A method for the continuous calculation of the age of labeled red blood cells. Am J Hematol 2008, 83:454-457.
66. Gladwin M.T., Schechter A.N., Ognibene F.P., Coles W.A., Reiter C.D., Schenke W.H., et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003, 107:271-278.
67. Reiter C.D., Wang X., Tanus-Santos J.E., Hogg N., Cannon R.O., Schechter A.N., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002, 8:1383-1389.
68. Morris C.R. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008, 177-185.
69. Franco R.S., Yasin Z., Palascak M.B., Ciraolo P., Joiner C.H., Rucknagel D.L. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 2006, 108:1073-1076.
70. Franco R.S., Yasin Z., Lohmann J.M., Palascak M.B., Nemeth T.A., Weiner M., et al. The survival characteristics of dense sickle cells. Blood 2000, 96:3610-3617.
71. Yasin Z., Witting S., Palascak M.B., Joiner C.H., Rucknagel D.L., Franco R.S. Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F. Blood 2003, 102:365-370.
72. Herman W.H., Cohen R.M. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012, 97:1067-1072.
73. Means R.T. Hepcidin and iron regulation in health and disease. Am J Med Sci 2013, 345:57-60.
74. Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 1823, 2012:1434-1443.
75. Sanad M., Osman M., Gharib A. Obesity modulate serum hepcidin and treatment outcome of iron deficiency anemia in children: a case control study. Ital J Pediatr 2011, 37:34.
76. Cartwright G.E. The anemia of chronic disorders. Semin Hematol 1966, 3:351-375.
77. Lee G.R. The anemia of chronic disease. Semin Hematol 1983, 20:61-80.
78. Mitlyng B.L., Singh J.A., Furne J.K., Ruddy J., Levitt M.D. Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases. Am J Hematol 2006, 81:432-438.
79. Strauss R.G., Widness J.A. Is there a role for autologous/placental red blood cell transfusions in the anemia of prematurity?. Transfus Med Rev 2010, 24:125-129.
80. Diekema D.S. Conducting ethical research in pediatrics: a brief historical overview and review of pediatric regulations. J Pediatr 2006, 149:S3-S11.
81. Mock D.M., Bell E.F., Lankford G.L., Widness J.A. Hematocrit correlates well with circulating red blood cell volume in very low birth weight infants. Pediatr Res 2001, 50:525-531.
82. Hudson I.R.B., Cavill I.A.J., Cooke A., Holland B.M., Hoy T.G., Trevett D., et al. Biotin labeling of red cells in the measurement of red cell volume in preterm infants. Pediatr Res 1990, 28:199-202.
83. Aladangady N., Aitchison T.C., Beckett C., Holland B.M., Kyle B.M., Wardrop C.A. Is it possible to predict the blood volume of a sick preterm infant?. Arch Dis Child Fetal Neonatal Ed 2004, 89:F344-F347.
84. Strauss R.G., Mock D.M., Johnson K., Mock N.I., Cress G., Knosp L., et al. Circulating RBC volume, measured with biotinylated RBCs, is superior to the Hct to document the hematologic effects of delayed versus immediate umbilical cord clamping in preterm neonates. Transfusion 2003, 43:1168-1172.
85. Strauss R.G., Mock D.M., Johnson K.J., Cress G.A., Burmeister L.F., Zimmerman M.B., et al. A randomized clinical trial comparing immediate versus delayed clamping of the umbilical cord in preterm infants: short-term clinical and laboratory endpoints. Transfusion 2008, 48:658-665.
86. Freas W. Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials 2008, Center for Biologics Evaluation and Research Blood Products Advisory Committee:US Food and Drug Administration.
87. Mock D.M., Widness J.A., Strauss R.G., Franco R.S. Posttransfusion red blood cell (RBC) survival determined using biotin-labeled RBCs has distinct advantages over labeling with (51) Cr. Transfusion 2012, 52:1596-1598.
88. Cordle D.G., Strauss R.G., Lankford G.L., Mock D.M. Antibodies provoked by the transfusion of biotin-labeled red cells. Transfusion 1999, 39:1065-1069.
89. Floss A.M., Strauss R.G., Goeken N., Knox L. Multiple transfusions fail to provoke antibodies against blood cell antigens in human infants. Transfusion 1986, 26:419-422.
90. Roseff S. Pediatric transfusion: a physician's handbook 2006, American Association of Blood Banks. 2nd ed.
91. Buchta C., Hanslik-Schnabel B., Weigl R., List J., Kormoczi G.F., Macher M., et al. Quality of drainage blood: survival of red cells after re-transfusion and content of free hemoglobin and potassium. Int J Surg 2005, 3:250-253.
92. Aladangady N., McHugh S., Aitchison T.C., Wardrop C.A., Holland B.M. Infants' blood volume in a controlled trial of placental transfusion at preterm delivery. Pediatrics 2006, 117:93-98.
93. Strauss R.G., Mock D.M., Widness J.A., Johnson K., Cress G., Schmidt R.L. Posttransfusion 24-hour recovery and subsequent survival of allogeneic red blood cells in the bloodstream of newborn infants. Transfusion 2004, 44:871-876.